Daniel I Bromage

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4427656/publications.pdf

Version: 2024-02-01

		448610	406436
51	1,466 citations	19	35
papers	citations	h-index	g-index
53	53	53	2589
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Impact of the COVID-19 pandemic on in-hospital mortality in cardiovascular disease: a meta-analysis. European Journal of Preventive Cardiology, 2022, 29, 1266-1274.	0.8	36
2	Patients hospitalised with heart failure across different waves of the COVID-19 pandemic show consistent clinical characteristics and outcomes. International Journal of Cardiology, 2022, 350, 125-129.	0.8	8
3	The right ventricular involvement in dilated cardiomyopathy: prevalence and prognostic implications of the often-neglected child. Heart Failure Reviews, 2022, 27, 1795-1805.	1.7	5
4	Nrf2 attenuates the innate immune response after experimental myocardial infarction. Biochemical and Biophysical Research Communications, 2022, 606, 10-16.	1.0	4
5	Cardiovascular outcomes associated with treatment of type 2 diabetes in patients with ischaemic heart failure. ESC Heart Failure, 2022, , .	1.4	2
6	Prevalence, Characteristics, and Outcomes of COVID-19–Associated Acute Myocarditis. Circulation, 2022, 145, 1123-1139.	1.6	118
7	Targeting Inflammation After Myocardial Infarctionâ€"Another Piece of the Puzzle. Journal of Cardiovascular Pharmacology, 2022, 79, 769-771.	0.8	1
8	<scp>COVIDâ€19</scp> and heart failure: the dark side of the moon. European Journal of Heart Failure, 2022, 24, 1129-1131.	2.9	4
9	Global longitudinal strain by <scp>CMR</scp> improves prognostic stratification in acute myocarditis presenting with normal <scp>LVEF</scp> . European Journal of Clinical Investigation, 2022, 52, .	1.7	6
10	Cardiovascular Damage in COVID-19: What We Know Two Years Later. Current Cardiology Reports, 2022, 24, 1085-1091.	1.3	4
11	The collateral cardiovascular damage of COVID-19: only history will reveal the depth of the iceberg. European Heart Journal, 2021, 42, 1524-1527.	1.0	21
12	Excess deaths in people with cardiovascular diseases during the COVID-19 pandemic. European Journal of Preventive Cardiology, 2021, 28, 1599-1609.	0.8	93
13	The innate immune response in myocarditis. International Journal of Biochemistry and Cell Biology, 2021, 134, 105973.	1.2	6
14	Prevalence and evolution of right ventricular dysfunction among different genetic backgrounds in dilated cardiomyopathy. Canadian Journal of Cardiology, 2021, 37, 1743-1750.	0.8	6
15	Longâ€term outcomes after heart failure hospitalization during the COVIDâ€19 pandemic: a multisite report from heart failure referral centers in London. ESC Heart Failure, 2021, 8, 4701-4704.	1.4	14
16	Generic ICD programming and outcomes. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 1995-2004.	0.5	3
17	Association between ethnicity and degree of improvement in cardiac function following initiation of sacubitril/valsartan. Journal of Cardiovascular Medicine, 2021, Publish Ahead of Print, 37-41.	0.6	3
18	$100 \hat{a} \in f$ Global longitudinal strain by CMR improves prognostic stratification in acute myocarditis presenting with normal LVEF. European Heart Journal Supplements, 2021, 23, .	0.0	1

#	Article	IF	CITATIONS
19	Cardiac monocytes and macrophages after myocardial infarction. Cardiovascular Research, 2020, 116, 1101-1112.	1.8	263
20	Temporal trends in decompensated heart failure and outcomes during $<$ scp>COVID $<$ /scp> \hat{a} \in 19: a multisite report from heart failure referral centres in $<$ scp>London $<$ /scp>. European Journal of Heart Failure, 2020, 22, 2219-2224.	2.9	86
21	Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment. BMC Medicine, 2020, 18, 103.	2.3	40
22	The impact of <scp>COVID</scp> â€19 on heart failure hospitalization and management: report from a Heart Failure Unit in London during the peak of the pandemic. European Journal of Heart Failure, 2020, 22, 978-984.	2.9	156
23	Cardiology after COVID-19: Quo Vademus?. European Heart Journal Quality of Care & Clinical Outcomes, 2020, 6, 208-209.	1.8	4
24	Therapies to limit myocardial injury in animal models of myocarditis: a systematic review and meta-analysis. Basic Research in Cardiology, 2019, 114, 48.	2.5	18
25	Heart failure guideline update: a guide for general practice. British Journal of General Practice, 2019, 69, 313-314.	0.7	0
26	Stromal cell-derived factor- $1\hat{l}\pm$ signals via the endothelium to protect the heart against ischaemia-reperfusion injury. Journal of Molecular and Cellular Cardiology, 2019, 128, 187-197.	0.9	17
27	Cardiac sarcoidosis in a patient with testicular seminoma. BMJ Case Reports, 2019, 12, e229912.	0.2	2
28	Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes: a cohort study. Cardiovascular Diabetology, 2019, 18, 168.	2.7	23
29	Therapeutic strategies utilizing SDF- $1\hat{l}_{\pm}$ in ischaemic cardiomyopathy. Cardiovascular Research, 2018, 114, 358-367.	1.8	36
30	6â€Comparing echocardiography and cardiac magnetic resonance measures of ejection fraction: implications for HFMRF research. , 2018, , .		7
31	19â€Diagnostic benefits of clinical CMR. , 2018, , .		0
32	Remote ischaemic conditioning reduces infarct size in animal <i>in vivo</i> models of ischaemia-reperfusion injury: a systematic review and meta-analysis. Cardiovascular Research, 2017, 113, cvw219.	1.8	71
33	Heritability of cerebral arterial velocity and resistance. Journal of Cardiovascular Medicine, 2017, 18, 28-33.	0.6	6
34	Ventilation strategy has a major influence on remote ischaemic preconditioning in mice. Journal of Cellular and Molecular Medicine, 2017, 21, 2426-2431.	1.6	2
35	A novel recombinant antibody specific to full-length stromal derived factor-1 for potential application in biomarker studies. PLoS ONE, 2017, 12, e0174447.	1.1	4
36	Ammonium tetrathiomolybdate following ischemia/reperfusion injury: Chemistry, pharmacology, and impact of a new class of sulfide donor in preclinical injury models. PLoS Medicine, 2017, 14, e1002310.	3.9	43

#	ARTICLE Late threabing Science posters657Aldehyde Dehydrogenase2 regulates senescence in the vascular	IF	CITATIONS
37	endothelium658Monoamine oxidase is over-activated in the left and right ventricles from human ischemic hearts: an intriguing therapeutic target659A novel assay for regulating transcription factors by flow660Remote ischaemic conditioning reduces infarct size in animal in vivo models of ischaemia-reperfusion injury: a systematic review and meta-analysis661The Role of Histone	1.8	1
38	Outcome of 1051 Octogenarian Patients With STâ€Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Observational Cohort From the London Heart Attack Group. Journal of the American Heart Association, 2016, 5, .	1.6	27
39	Exogenous SDF- $1\hat{1}$ ± Protects Human Myocardium from Hypoxia-Reoxygenation Injury via CXCR4. Cardiovascular Drugs and Therapy, 2015, 29, 589-592.	1.3	15
40	Time-Trend Analyses of Bleeding and Mortality After Primary Percutaneous Coronary Intervention During Out of Working Hours Versus In-Working Hours. Circulation: Cardiovascular Interventions, 2015, 8, e002206.	1.4	2
41	The pleiotropic effects of metformin: time for prospective studies. Cardiovascular Diabetology, 2015, 14, 109.	2.7	30
42	Prognostic impact of anaemia on patients with ST-elevation myocardial infarction treated by primary PCI. Coronary Artery Disease, 2014, 25, 52-59.	0.3	26
43	Culprit Vessel Versus Multivessel Intervention at the Time of Primary Percutaneous Coronary Intervention in Patients With ST-Segment-Elevation Myocardial Infarction and Multivessel Disease: Real-World Analysis of 3984 Patients in London. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 936-943.	0.9	38
44	Radial Versus Femoral Access Is Associated With Reduced Complications and Mortality in Patients With Non–ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2014, 7, 456-464.	1.4	30
45	Stromal derived factor $1\hat{l}\pm$: A chemokine that delivers a two-pronged defence of the myocardium. , 2014, 143, 305-315.		82
46	Radial primary percutaneous coronary intervention is independently associated with decreased long-term mortality in high-risk ST-elevation myocardial infarction patients. Journal of Cardiovascular Medicine, 2014, Publish Ahead of Print, .	0.6	1
47	Out-of-hours primary percutaneous coronary intervention for ST-elevation myocardial infarction is not associated with excess mortality: a study of 3347 patients treated in an integrated cardiac network. BMJ Open, 2013, 3, e003063.	0.8	23
48	New technologies aimed at percutaneous intervention in the small coronary artery. Expert Review of Cardiovascular Therapy, 2012, 10, 441-455.	0.6	0
49	Improving informed consent in percutaneous coronary revascularisation. EuroIntervention, 2012, 8, 146-154.	1.4	1
50	Anomalous right coronary artery originating from the left main stem. BMJ Case Reports, 2011, 2011, bcr1120103510-bcr1120103510.	0.2	1
51	Prenatal diagnosis and selective abortion: a result of the cultural turn?. Medical Humanities, 2006, 32, 38-42.	0.6	6